CL2022003744A1 - Métodos para tratar la alergia usando anticuerpos anti-bet v 1 - Google Patents

Métodos para tratar la alergia usando anticuerpos anti-bet v 1

Info

Publication number
CL2022003744A1
CL2022003744A1 CL2022003744A CL2022003744A CL2022003744A1 CL 2022003744 A1 CL2022003744 A1 CL 2022003744A1 CL 2022003744 A CL2022003744 A CL 2022003744A CL 2022003744 A CL2022003744 A CL 2022003744A CL 2022003744 A1 CL2022003744 A1 CL 2022003744A1
Authority
CL
Chile
Prior art keywords
bet
antibodies
methods
treat allergy
antigen
Prior art date
Application number
CL2022003744A
Other languages
English (en)
Spanish (es)
Inventor
Atanasio Amanda
Herman Gary
P O'brien Meagan
M Orengo Jamie
Perlee Lorah
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2022003744A1 publication Critical patent/CL2022003744A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CL2022003744A 2020-07-01 2022-12-23 Métodos para tratar la alergia usando anticuerpos anti-bet v 1 CL2022003744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047126P 2020-07-01 2020-07-01
US202063129253P 2020-12-22 2020-12-22

Publications (1)

Publication Number Publication Date
CL2022003744A1 true CL2022003744A1 (es) 2023-06-02

Family

ID=77168400

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003744A CL2022003744A1 (es) 2020-07-01 2022-12-23 Métodos para tratar la alergia usando anticuerpos anti-bet v 1

Country Status (12)

Country Link
US (2) US11897945B2 (enExample)
EP (1) EP4175986A1 (enExample)
JP (1) JP7897809B2 (enExample)
KR (1) KR20230030573A (enExample)
CN (1) CN115698059A (enExample)
AU (1) AU2021300129A1 (enExample)
BR (1) BR112022026279A2 (enExample)
CA (1) CA3177918A1 (enExample)
CL (1) CL2022003744A1 (enExample)
IL (1) IL299207A (enExample)
MX (1) MX2022015677A (enExample)
WO (1) WO2022006305A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
US11897945B2 (en) 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2026125663A2 (en) * 2024-12-11 2026-06-18 Mabylon Ag Anti-allergen antibodies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1219299T4 (da) 2000-12-28 2011-02-14 Biomay Ag Allergivacciner og fremstilling deraf
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
WO2010089671A2 (en) * 2009-02-09 2010-08-12 Anergis S.A. Contiguous overlapping peptides for treatment of birch pollen allergy
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3036543B1 (en) 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
CN108129558B (zh) * 2017-12-21 2021-10-12 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
US11897945B2 (en) 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
CN121241065A (zh) * 2023-03-31 2025-12-30 爱尔开-阿贝优公司 适用于治疗树木花粉过敏的过敏原结合抗体
WO2025165851A1 (en) 2024-01-30 2025-08-07 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Also Published As

Publication number Publication date
US12583914B2 (en) 2026-03-24
WO2022006305A1 (en) 2022-01-06
KR20230030573A (ko) 2023-03-06
JP7897809B2 (ja) 2026-07-30
US11897945B2 (en) 2024-02-13
JP2023531968A (ja) 2023-07-26
BR112022026279A2 (pt) 2023-02-14
MX2022015677A (es) 2023-02-22
EP4175986A1 (en) 2023-05-10
US20240209074A1 (en) 2024-06-27
IL299207A (en) 2023-02-01
CA3177918A1 (en) 2022-01-06
CN115698059A (zh) 2023-02-03
AU2021300129A1 (en) 2022-12-08
US20220002394A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
MX2022015677A (es) Metodos para tratar la alergia usando anticuerpos anti-bet v 1.
CL2024002250A1 (es) Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria.
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
MX2022001156A (es) Anticuerpos que se fijan a gprc5d.
BR112014008764A2 (pt) composições para o tratamento de artrite reumatóide e métodos de seu uso
EA033072B1 (ru) Применение антител к семафорину 4d для лечения болезни хантингтона
EA201592042A1 (ru) Композиции антител против cgrp и их применение
EA201692192A1 (ru) СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BR112021018451A2 (pt) Anticorpo biespecífico especificamente ligado a vegf e ang2
CR20170096A (es) Tratamientos conjuntos con anticuerpos anti cd40
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
EA201070539A1 (ru) НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
MX2022016039A (es) Anticuerpos anti-cd2.
MX2024008933A (es) Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
PY2018606A (es) Anticuerpo monoclonal que se une específicamente a GITR
ZA202302084B (en) Antibody that binds to vegf-a and ang2 and methods of use
CO2021000386A2 (es) Anticuerpos humanizados contra psma
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
CL2021003335A1 (es) Anticuerpo biespecífico para a-syn/igf1r y uso de este.
MX2022012913A (es) Anticuerpo anti-ox40 y usos del mismo.
MX2024015304A (es) Terapias combinadas con un anticuerpo antifactor xi/factor xia
DOP2022000129A (es) Anticuerpos contra la integrina alfa 11 beta 1
PE20230602A1 (es) Anticuerpos anti-sea de muc1
WO2023288204A8 (en) Diagnostics for porphyromonas gingivalis